134 related articles for article (PubMed ID: 37399589)
1. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression.
Keske A; Shetty S; Weisman P; Yu Q; McGregor SM; Xu J
Pathol Res Pract; 2023 Aug; 248():154628. PubMed ID: 37399589
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
Weisman P; Yu Q; Xu J
Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
[TBL] [Abstract][Full Text] [Related]
3. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
4. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status.
Vellaisamy G; Tirumalae R; Inchara YK
J Cancer Res Ther; 2019; 15(5):989-993. PubMed ID: 31603099
[TBL] [Abstract][Full Text] [Related]
5. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance.
Gong Y; Wei W; Wu Y; Ueno NT; Huo L
Cancer; 2014 Jun; 120(12):1775-9. PubMed ID: 24634055
[TBL] [Abstract][Full Text] [Related]
6. FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction.
Li M; Zhou S; Lv H; Cai M; Wan X; Lu H; Shui R; Yang W
Arch Pathol Lab Med; 2024 Apr; 148(4):461-470. PubMed ID: 37406289
[TBL] [Abstract][Full Text] [Related]
7. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
8. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
[TBL] [Abstract][Full Text] [Related]
9. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
11. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
12. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
[TBL] [Abstract][Full Text] [Related]
13. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
Chiu K; Ionescu DN; Hayes M
Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273
[TBL] [Abstract][Full Text] [Related]
14. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
15. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
16. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
[TBL] [Abstract][Full Text] [Related]
18. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
[TBL] [Abstract][Full Text] [Related]
19. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
20. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]